These include: Toxicity Concerns: Systemic activation risks cytokine release syndrome (CRS) and inflammatory toxicities driven by IFN-I and IL-6, necessitating optimized dosing and delivery strategies. This evidence concerns the gene IL6 and congenital rubella syndrome.